Ryan CJ - Search Results

1

Persistent prostate-specific antigen expression after neoadjuvant androgen depletion: an early predictor of relapse or incomplete androgen suppression.

Ryan CJ, Smith A, Lal P, Satagopan J, Reuter V, Scardino P, Gerald W, Scher HI. Ryan CJ, et al. Urology. 2006 Oct;68(4):834-9. doi: 10.1016/j.urology.2006.04.016. Urology. 2006. PMID: 17070363

2

Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance.

Holzbeierlein J, Lal P, LaTulippe E, Smith A, Satagopan J, Zhang L, Ryan C, Smith S, Scher H, Scardino P, Reuter V, Gerald WL. Holzbeierlein J, et al. Am J Pathol. 2004 Jan;164(1):217-27. doi: 10.1016/S0002-9440(10)63112-4. Am J Pathol. 2004. PMID: 14695335 Free PMC article.

3

Role of secondary hormonal therapy in the management of recurrent prostate cancer.

Ryan CJ, Small EJ. Ryan CJ, et al. Urology. 2003 Dec 29;62 Suppl 1:87-94. doi: 10.1016/j.urology.2003.10.002. Urology. 2003. PMID: 14747046

4

Advances in prostate cancer.

Ryan CJ, Small EJ. Ryan CJ, et al. Curr Opin Oncol. 2004 May;16(3):242-6. doi: 10.1097/00001622-200405000-00009. Curr Opin Oncol. 2004. PMID: 15069320 Review.

5

Five-year outcomes after neoadjuvant chemotherapy and conformal radiotherapy in patients with high-risk localized prostate cancer.

Ryan CJ, Zelefsky MJ, Heller G, Regan K, Leibel SA, Scher HI, Kelly WK. Ryan CJ, et al. Urology. 2004 Jul;64(1):90-4. doi: 10.1016/j.urology.2004.03.006. Urology. 2004. PMID: 15245942 Clinical Trial.

6

High risk biochemical relapse and the timing of androgen deprivation therapy.

Ryan CJ, Small EJ. Ryan CJ, et al. J Urol. 2006 Dec;176(6 Pt 2):S61-5. doi: 10.1016/j.juro.2006.06.072. J Urol. 2006. PMID: 17084171 Review.

7

The case for secondary hormonal therapies in the chemotherapy age.

Small EJ, Ryan CJ. Small EJ, et al. Among authors: ryan cj. J Urol. 2006 Dec;176(6 Pt 2):S66-71. doi: 10.1016/j.juro.2006.06.071. J Urol. 2006. PMID: 17084172 Review.

8

Innovations and challenges in prostate cancer: summary statement for the 6th Cambridge Conference.

Kantoff PW, Beer TM, D'Amico AV, Dipaola RS, Eisenberger MA, Hussain MH, Kelly WK, Mathew P, Morris MJ, Ryan CJ, Sandler HM, Thompson IM, Carroll PR. Kantoff PW, et al. Among authors: ryan cj. J Urol. 2007 Sep;178(3 Pt 2):S5-8; quiz S4. doi: 10.1016/j.juro.2007.03.137. Epub 2007 Jul 20. J Urol. 2007. PMID: 17644118 No abstract available.

9

Prostate specific antigen only androgen independent prostate cancer: natural history, challenges in management and clinical trial design.

Ryan CJ, Beer TM. Ryan CJ, et al. J Urol. 2007 Sep;178(3 Pt 2):S25-9. doi: 10.1016/j.juro.2007.03.136. Epub 2007 Jul 20. J Urol. 2007. PMID: 17644122 Review.

10

Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome.

Ryan CJ, Weinberg V, Rosenberg J, Fong L, Lin A, Kim J, Small EJ. Ryan CJ, et al. J Urol. 2007 Dec;178(6):2372-6; discussion 2377. doi: 10.1016/j.juro.2007.08.011. Epub 2007 Oct 22. J Urol. 2007. PMID: 17936834 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

473 results

Search Page

Filters